While the company no longer manufactures the radiographic markers, healthcare providers are still advised to monitor patients who have had them implanted.

FDA warns of a breast biopsy needle shortage through March 2027 due to a Hologic recall. Learn how this affects patient care ...

We have always firmly believed that our success as a company is fundamentally tied to our ability and commitment to help ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a company that develops industry-leading technologies that detect, diagnose and treat life-changing health conditions that affect ...

Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology ...

Medical technology company Hologic (NASDAQ:HOLX) in Q4 CY2024, but sales were flat year on year at $1.02 billion. On the other hand, next quarter’s revenue guidance of $1 billion was less impressive, ...

Hologic (HOLX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) will reveal new technologies reimagining the future of breast health at the 110 th Scientific Assembly and Annual Meeting of the ...

Hologic’s recall of its BioZorb Markers due to complications with the implanted device were recently identified as Class I by FDA after 71 injuries were reported as being related to BioZorb Markers.

Report outlines actions helping to reduce environmental impact, advance health equity and engage a purpose-driven workforce Hologic, Inc., a global leader in women's health, today released its 2025 ...